Overview
Publication
PLOS ONE. 2010 Oct 27; 5(10):e13579.
PubMed ID: 21048953
Title
Safety and immunogenicity of a single-dose recombinant adenovirus type 5 multiclade HIV-1 vaccine in persons without previous vector immunity: A randomized clinical trial (HVTN study 054)
Authors
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, DeRosa SC, McElrath MJ
Abstract
Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior immunity, we evaluated a recombinant replication-defective adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, in a randomized, double-blind, dose-escalation, multicenter trial (HVTN study 054) in HIV-1-seronegative participants without detectable neutralizing antibodies (nAb) to the vector. As secondary outcomes, we also assessed T-cell and antibody responses.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.